Jump to content

In silico clinical trials

From Wikipedia, the free encyclopedia

An in silico clinical trial, also known as a virtual clinical trial, is an individualized computer simulation used in the development or regulatory evaluation of a medicinal product, device, or intervention. While completely simulated clinical trials are not feasible with current technology and understanding of biology, its development would be expected to have major benefits over current in vivo clinical trials, and research on it is being pursued.

History

[edit]

The term in silico indicates any use of computers in clinical trials, even if limited to management of clinical information in a database.[1]

Rationale

[edit]

The traditional model for the development of medical treatments and devices begins with pre-clinical development. In laboratories, test-tube and other in vitro experiments establish the plausibility for the efficacy of the treatment. Then in vivo animal models, with different species, provide guidance on the efficacy and safety of the product for humans. With success in both in vitro and in vivo studies, scientist can propose that clinical trials test whether the product be made available for humans. Clinical trials are often divided into four phases. Phase 3 involves testing a large number of people.[2] When a medication fails at this stage, the financial losses can be catastrophic.[3]

Predicting low-frequency side effects has been difficult, because such side effects need not become apparent until the treatment is adopted by many patients. The appearance of severe side-effects in phase three often causes development to stop, for ethical and economic reasons.[2][4][5] Also, in recent years many candidate drugs failed in phase 3 trials because of lack of efficacy rather than for safety reasons.[2][3] One reason for failure is that traditional trials aim to establish efficacy and safety for most subjects, rather than for individual subjects, and so efficacy is determined by a statistic of central tendency for the trial. Traditional trials do not adapt the treatment to the covariates of subjects:

  • Taking account of factors such as the patient's particular physiology, the individual manifestation of the disease being treated, their lifestyle, and the presence of co-morbidities.[4][6]
  • Compliance, or lack thereof, in taking the drug at the times and dose prescribed. In the case of a surgically implanted device, to account for the variability in surgeons’ experience and technique, as well as the particular anatomy of the patient.[7] However, adjusting the evaluation of the study for noncompliance has proved difficult. Such adjustments often bias the results of the study, and so many health authorities mandate that clinical trials analyse the data according to the intention to treat principle.

Aim

[edit]

Accurate computer models of a treatment and its deployment, as well as patient characteristics, are necessary precursors for the development of in silico clinical trials.[5][6][8][9] In such a scenario, ‘virtual’ patients would be given a ‘virtual’ treatment, enabling observation through a computer simulation of how the candidate biomedical product performs and whether it produces the intended effect, without inducing adverse effects. Such in silico clinical trials could help to reduce, refine, and partially replace real clinical trials by:

  • Reducing the size and the duration of clinical trials through better design,[6][8] for example, by identifying characteristics to determine which patients might be at greater risk of complications or providing earlier confirmation that the product[5] or process[10] is working as expected.
  • Refining clinical trials through clearer, more detailed information on potential outcomes and greater explanatory power in interpreting any adverse effects that might emerge, as well as better understanding of how the tested product interacts with the individual patient anatomy and predicting long-term or rare effects that clinical trials are unlikely to reveal.[9]
  • Partially replacing clinical trials in those situations where it is not an absolute regulatory necessity, but only a legal requirement. There are already examples where regulators have accepted the replacement of animal models with in silico models under appropriate conditions.[11] While real clinical trials will remain essential in most cases, there are specific situations where a reliable predictive model can conceivably replace a routine clinical assessment.

In addition, real clinical trials may indicate that a product is unsafe or ineffective, but rarely indicate why or suggest how it might be improved. As such, a product that fails during clinical trials may simply be abandoned, even if a small modification would solve the problem. This stifles innovation, decreasing the number of truly original biomedical products presented to the market every year, and at the same time increasing the cost of development.[12] Analysis through in silico clinical trials is expected to provide a better understanding of the mechanism that caused the product to fail in testing,[8][13] and may be able to provide information that could be used to refine the product to such a degree that it could successfully complete clinical trials.

In silico clinical trials would also provide significant benefits over current pre-clinical practices. Unlike animal models, the virtual human models can be re-used indefinitely, providing significant cost savings. Compared to trials in animals or a small sample of humans, in silico trials might more effectively predict the behaviour of the drug or device in large-scale trials, identifying side effects that were previously difficult or impossible to detect, helping to prevent unsuitable candidates from progressing to the costly phase 3 trials.[12]

In radiology

[edit]

One relatively well-developed field of in-silico clinical trials is radiology, where the entire imaging process is digitized.[14][15] The development has accelerated in recent years following the growth of computer capacity and more advanced simulation models, and is now at the point that virtual platforms are gaining acceptance by regulatory bodies as a complement to conventional clinical trials for new product introductions.[16]

A complete framework for in-silico clinical trials in radiology needs to include the following three components: 1) A realistic patient population, which is computer simulated using software phantoms; 2) The simulated response of the imaging system; 3) Image evaluation in a systematic way by human or model observers.[14][15]

Computational phantoms for imaging in-silico trials require a high degree of realism because images will be produced and evaluated. To date, the most realistic whole-body phantoms are so-called boundary representation (BREP) phantoms, which are surface representations of segmented 3D patient data (MRI or CT).[17] The fitted surfaces allow for modelling anatomical changes or motion in addition to realistic anatomy. Existing models for generating intra-organ structures are based on mathematical modelling, patient images, or generative adversarial network (GAN) modelling of patient images.[16][18] Models of pathologies are important for simulating clinical applications targeted on specific diseases. State-of-the-art models are based on segmented lesions with enhancements for structures above the resolution limit of the imaging system using digital pathology or physiological growth models.[19] GAN models have been used to simulate disease as well.[20] In addition to the above, models have been developed for organ and patient motion, blood flow and contrast agent perfusion.

The response of the imaging system is generally simulated with Monte-Carlo or raytracing system models, benchmarked to measurements on physical phantoms.[21][22] Medical imaging has a long history of system simulation for technology development and proprietary as well as public-domain models exist for a wide range of imaging systems.

The final step of an imaging in-silico trial is evaluation and interpretation of the generated images in a systematic way. The images can be evaluated by humans in ways similar to a conventional clinical trial, but for an in-silico trial to be really effective, image interpretation as well needs to be automized. For detection and quantification tasks, so-called observer models have been thoroughly studied and validated against human observers, and a range of spatial-domain models exist in the literature.[23] Image interpretation based on deep learning and artificial intelligence (AI) is an active research field,[24] and might become a valuable aid for the radiologist to find abnormalities or to make decisions. Applying AI observers in in-silico trials is relatively straightforward as the entire image chain is digitized.

See also

[edit]

References

[edit]

 This article incorporates text available under the CC BY 4.0 license.

  1. ^ This sense of the term was used in 2011 in a position paper from the VPH Institute commenting on the green paper written ahead of the launch of the European Commission Horizon 2020 framework programme. VPH greenpaper
  2. ^ a b c Arrowsmith J, Miller P (August 2013). "Trial watch: phase II and phase III attrition rates 2011-2012". Nature Reviews. Drug Discovery. 12 (8): 569. doi:10.1038/nrd4090. PMID 23903212.
  3. ^ a b Milligan PA, Brown MJ, Marchant B, Martin SW, van der Graaf PH, Benson N, et al. (June 2013). "Model-based drug development: a rational approach to efficiently accelerate drug development". Clinical Pharmacology and Therapeutics. 93 (6): 502–514. doi:10.1038/clpt.2013.54. PMID 23588322. S2CID 29806156.
  4. ^ a b Harnisch L, Shepard T, Pons G, Della Pasqua O (February 2013). "Modeling and simulation as a tool to bridge efficacy and safety data in special populations". CPT: Pharmacometrics & Systems Pharmacology. 2 (2): 1–4. doi:10.1038/psp.2013.6. PMC 3600759. PMID 23835939.
  5. ^ a b c Davies MR, Mistry HB, Hussein L, Pollard CE, Valentin JP, Swinton J, Abi-Gerges N (April 2012). "An in silico canine cardiac midmyocardial action potential duration model as a tool for early drug safety assessment". American Journal of Physiology. Heart and Circulatory Physiology. 302 (7): H1466–H1480. doi:10.1152/ajpheart.00808.2011. PMID 22198175.
  6. ^ a b c Hunter P, Chapman T, Coveney PV, de Bono B, Diaz V, Fenner J, et al. (April 2013). "A vision and strategy for the virtual physiological human: 2012 update". Interface Focus. 3 (2): 20130004. doi:10.1098/rsfs.2013.0004. PMC 3638492. PMID 24427536.
  7. ^ Viceconti M, Affatato S, Baleani M, Bordini B, Cristofolini L, Taddei F (January 2009). "Pre-clinical validation of joint prostheses: a systematic approach". Journal of the Mechanical Behavior of Biomedical Materials. 2 (1): 120–127. doi:10.1016/j.jmbbm.2008.02.005. PMID 19627814.
  8. ^ a b c Erdman AG, Keefe DF, Schiestl R (March 2013). "Grand challenge: applying regulatory science and big data to improve medical device innovation". IEEE Transactions on Bio-Medical Engineering. 60 (3): 700–706. doi:10.1109/TBME.2013.2244600. PMID 23380845. S2CID 442791.
  9. ^ a b Clermont G, Bartels J, Kumar R, Constantine G, Vodovotz Y, Chow C (October 2004). "In silico design of clinical trials: a method coming of age". Critical Care Medicine. 32 (10): 2061–2070. doi:10.1097/01.CCM.0000142394.28791.C3. PMID 15483415. S2CID 10952248.
  10. ^ Agarwal Y (2019-02-15). "New Technological Breakthroughs for Patient-Specific Healthcare and Schizophrenia". ETHealthworld.com. Retrieved 2019-04-01.
  11. ^ Kovatchev BP, Breton M, Man CD, Cobelli C (January 2009). "In silico preclinical trials: a proof of concept in closed-loop control of type 1 diabetes". Journal of Diabetes Science and Technology. 3 (1): 44–55. doi:10.1177/193229680900300106. PMC 2681269. PMID 19444330.
  12. ^ a b Viceconti M, Morley-Fletcher E, Henney A, Contin M, El-Arifi K, McGregor C, Karlstrom A, Wilkinson E. "In Silico Clinical Trials: How Computer Simulation Will Transform The Biomedical Industry An international research and development roadmap for an industry-driven initiative" (PDF). Avicenna-ISCT. Avicenna Project. Retrieved 1 June 2015.
  13. ^ Manolis E, Rohou S, Hemmings R, Salmonson T, Karlsson M, Milligan PA (February 2013). "The Role of Modeling and Simulation in Development and Registration of Medicinal Products: Output From the EFPIA/EMA Modeling and Simulation Workshop". CPT: Pharmacometrics & Systems Pharmacology. 2 (2): 1–4. doi:10.1038/psp.2013.7. PMC 3600760. PMID 23835942.
  14. ^ a b Abadi E, Segars WP, Tsui BM, Kinahan PE, Bottenus N, Frangi AF, et al. (July 2020). "Virtual clinical trials in medical imaging: a review". Journal of Medical Imaging. 7 (4): 042805. doi:10.1117/1.JMI.7.4.042805. PMC 7148435. PMID 32313817.
  15. ^ a b Maidment DA (2014). "Virtual Clinical Trials for the Assessment of Novel Breast Screening Modalities". In Fujita H, Hiroshi H, Takeshi M, Muramatsu C (eds.). Breast Imaging. Lecture Notes in Computer Science. Vol. 8539. Cham: Springer International Publishing. pp. 1–8. doi:10.1007/978-3-319-07887-8_1. ISBN 978-3-319-07886-1.
  16. ^ a b Glick SJ, Ikejimba LC (October 2018). "Advances in digital and physical anthropomorphic breast phantoms for x-ray imaging". Medical Physics. 45 (10): e870–e885. Bibcode:2018MedPh..45E.870G. doi:10.1002/mp.13110. PMID 30058117. S2CID 51865533.
  17. ^ Segars WP, Sturgeon G, Mendonca S, Grimes J, Tsui BM (September 2010). "4D XCAT phantom for multimodality imaging research". Medical Physics. 37 (9): 4902–4915. Bibcode:2010MedPh..37.4902S. doi:10.1118/1.3480985. PMC 2941518. PMID 20964209.
  18. ^ Chang Y, Lafata K, Segars WP, Yin FF, Ren L (March 2020). "Development of realistic multi-contrast textured XCAT (MT-XCAT) phantoms using a dual-discriminator conditional-generative adversarial network (D-CGAN)". Physics in Medicine and Biology. 65 (6): 065009. Bibcode:2020PMB....65f5009C. doi:10.1088/1361-6560/ab7309. PMC 7252912. PMID 32023555.
  19. ^ Sauer TJ, Samei E (2019-03-14). "Modeling dynamic, nutrient-access-based lesion progression using stochastic processes". In Bosmans H, Chen GH, Gilat Schmidt T (eds.). Medical Imaging 2019: Physics of Medical Imaging. Vol. 10948. SPIE. pp. 1193–1200. Bibcode:2019SPIE10948E..50S. doi:10.1117/12.2513201. ISBN 9781510625433. S2CID 92553165.
  20. ^ Sauer TJ, Richards TW, Buckler AJ, Daubert M, Douglas P, Segars WP, Samei E (2020-03-16). Bosmans H, Chen JH (eds.). "Synthesis of physiologically-informed computational coronary artery plaques for use in virtual clinical trials (Conference Presentation)". Medical Imaging 2020: Physics of Medical Imaging. 11312. SPIE: 113121X. doi:10.1117/12.2550011. ISBN 9781510633919. S2CID 216439674.
  21. ^ Badal A, Badano A (October 2009). "Monte Carlo simulation of X-ray imaging using a graphics processing unit". 2009 IEEE Nuclear Science Symposium Conference Record (NSS/MIC). pp. 4081–4084. doi:10.1109/NSSMIC.2009.5402382. ISBN 978-1-4244-3961-4. S2CID 9960455.
  22. ^ di Franco F, Sarno A, Mettivier G, Hernandez AM, Bliznakova K, Boone JM, Russo P (June 2020). "GEANT4 Monte Carlo simulations for virtual clinical trials in breast X-ray imaging: Proof of concept". Physica Medica. 74: 133–142. doi:10.1016/j.ejmp.2020.05.007. PMID 32470909. S2CID 219105424.
  23. ^ Abbey CK, Barrett HH (March 2001). "Human- and model-observer performance in ramp-spectrum noise: effects of regularization and object variability". Journal of the Optical Society of America A. 18 (3): 473–488. Bibcode:2001JOSAA..18..473A. doi:10.1364/JOSAA.18.000473. PMC 2943344. PMID 11265678.
  24. ^ Rajkomar A, Dean J, Kohane I (April 2019). "Machine Learning in Medicine". The New England Journal of Medicine. 380 (14): 1347–1358. doi:10.1056/NEJMra1814259. PMID 30943338. S2CID 92996321.
[edit]
Retrieved from "https://en.wikipedia.org/w/index.php?title=In_silico_clinical_trials&oldid=1262415704"